Abstracts tagged "proteinuria and systemic lupus erythematosus (SLE)"

Abstract Number: 761 • 2018 ACR/ARHP Annual Meeting
Protein/Creatinin Urinary Index Has Concordance with 24 Hour Urinary Proteinuria in Patients with Systemic Lupus Erythematosus
Eugenia Picco¹, Ricardo Vicente Juárez², Emilio Buschiazzo², Natalia Lili Cucchiaro³, Gustavo Rua⁴, Patricia Talocchino¹, Ivana Romina Rojas Tessel¹, Mariana Aciar³, Maria Veronica Lencina³ and Maria Elena Crespo Espindola⁵, ¹Hospital Señor del Milagro, Salta, Argentina, ²Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ³Rheumatology, Hospital Señor del Milagro, Salta, Argentina, ⁴Biochemistry Section, Hospital Señor del Milagro, Salta, Argentina, ⁵Reumatologia, Hospital Señor del Milagro, Salta, Argentina
Background/Purpose: Twenty-four hour proteinuria (24hp) has been the gold standard for the screening and follow up of glomerular disease. The use of protein/creatinin urinary index…
Abstract Number: 403 • 2015 ACR/ARHP Annual Meeting
Proteinuria in Childhood Onset Lupus Nephritis: When Does It Go Away ?
Justin Hung Tiong Tan¹, Sook Fun Hoh², Manasita Tanya¹, Lena Das¹, Ma Thin Mar Win³, Yiong Huak Chan³ and Thaschawee Arkachaisri^1,4, ¹Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ³Biostatistics Unit, Yong Loo Lin School of Medicine, Singapore, Singapore, ⁴Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore
Background/Purpose: The time to recovery from proteinuria in patients with lupus nephritis (LN) receiving standard treatment has been described in adult, but not in children.…
Abstract Number: 1776 • 2015 ACR/ARHP Annual Meeting
Significantly Reduced Lymphadenopathy, Salivary Gland Infiltrates and Proteinuria in MRL-Lpr/Lpr Mice Treated with Ultrasoluble Curcumin/Turmeric: Increased Survival with Curcumin Treatment
Biji T Kurien^1,2,3, Valerie M Harris^1,4, Syed MS Quadri^1,4, Patricia Coutinho-de Souza¹, Joshua Cavett^5,6, Amanda Moyer⁴, Bilal Ittiq⁷, Angela Metcalf⁶, Husayn Ramji⁸, Dat Truong⁸, Kristi A. Koelsch^4,9,10, Mike Centola¹¹, Adam Payne¹², D. Danda¹³ and R. Hal Scofield^1,14, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Allergy and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷University of Oklahoma Health Sciences Center, Oklahoma, OK, ⁸University of Oklahoma, Oklahoma City, OK, ⁹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ¹⁰Department Veterans Affairs Medical Center, Oklahoma City, OK, ¹¹Haus Bioceuticals, Oklahoma City, OK, ¹²Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ¹³Christian Medical College, Vellore, India, ¹⁴US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Commercial curcumin (CU), derived from food spice turmeric, has been widely studied as a potential therapeutic for a variety of oncological and inflammatory conditions.…
Abstract Number: 2904 • 2015 ACR/ARHP Annual Meeting
Utility of Untimed Single Urine Protein/Creatinine Ratio As a Substitute for the 24 Hour Proteinuria for the Assessment of Proteinuria in Systemic Lupus Erythematosus
Jorge Medina-Rosas¹, Dafna Gladman², Jiandong Su², Arthy Sabapathy³ and Murray Urowitz^2,4, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: To determine the utility of an untimed Sample of Urine Protein/Creatinine ratio (S-UPCR) as a screening test for proteinuria and its ability to accurately…
Abstract Number: 2905 • 2015 ACR/ARHP Annual Meeting
Urinary Protein:Urinary Creatinine Ratio in an Untimed Urine Specimen and Estimated Glomerular Filtration Rate Are Reliable Measures of Proteinuria and Renal Function in Patients with Lupus Nephritis
Yasuhiro Katsumata, Hirokazu Nishina, Masanori Hanaoka, Yasushi Kawaguchi, Kae Takagi, Akiko Tochimoto, Yuki Ichimura and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Renal Disease Subcommittee of the American College of Rheumatology (ACR) Ad Hoc Committee on Systemic Lupus Erythematosus (SLE) has recommended the urinary protein level…
Abstract Number: 2908 • 2015 ACR/ARHP Annual Meeting
Diagnostic and Screening Accuracy of Spot Urinary Protein-Creatinine Ratio Compared to Protein Content in a 24 Hour-Urine Collection in Systemic Lupus Erythematosus: Systematic Review and Meta-Analysis
Jorge Medina-Rosas¹, Kristy Yap², Melanie Anderson³, Jiandong Su² and Zahi Touma², ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Library and Information Services, University Health Network, University Health Network, Toronto, ON, Canada
Background/Purpose: To systematically review literature on the utility of spot urinary protein-creatinine ratio (PCR) as a screening test for proteinuria and its ability to accurately…
Abstract Number: 2910 • 2015 ACR/ARHP Annual Meeting
How Accurate Is Spot Urine Protein/Creatinine Ratio in Measuring the Change over Time in Proteinuria Level Compared to the 24 Hour Proteinuria Test?
Jorge Medina-Rosas¹, Murray Urowitz^2,3, Jiandong Su², Dafna Gladman² and Zahi Touma², ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The Protein/Creatinine ratio in a spot urine sample (PCR) has been accepted as a substitute for the protein content in a 24 hours urine…
Abstract Number: 2918 • 2015 ACR/ARHP Annual Meeting
Do Patients with Lupus Nephritis Who Achieve Complete Proteinuria Recovery at 2 Years Have Better Long Term Outcomes Compared to Patients with Partial Proteinuria Recovery?
Zahi Touma¹, Murray Urowitz^2,3, Jorge Medina-Rosas⁴, Jiandong Su¹ and Dafna Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The tempo of Complete Proteinuria Recovery (CPR) in Lupus Nephritis (LN) is slow and while 28% achieve CPR at year 1 this increases to…
Abstract Number: 841 • 2012 ACR/ARHP Annual Meeting
Effect of Partial and Complete Proteinuria Recovery in Lupus Nephritis On Long Term Outcomes
Zahi Touma¹, Murray B. Urowitz², Dominique Ibanez² and D. D. Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The identification of partial proteinuria recovery (PPR) of ≥ 50% allows for the detection of an additional number of patients who improve their proteinuria…
Abstract Number: 2678 • 2012 ACR/ARHP Annual Meeting
Novel Nuclear Export Inhibitors Deplete Autoreactive Plasma Cells and Protect Mice with Lupus-Like Disease From Nephritis
Teresa Owen¹, Wensheng Wang¹, Dilara McCauley², Laura Strojny¹, Jennifer Hossler¹, Javier Rangel-Moreno³, Michael Kauffman², Sharon Shacham⁴ and Jennifer H. Anolik⁵, ¹Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Karyopharm, Therapeutics Inc., Natick, MA, ³Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ⁴Karyopharm Therapeutics Inc., Natick, MA, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Most therapies currently used to treat systemic lupus erythematosus (SLE) and B cell targeted therapies under development do not effectively target plasma cells and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].